Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$36.71 USD
+0.29 (0.80%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $36.73 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$36.71 USD
+0.29 (0.80%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $36.73 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Zacks News
Valeant (VRX) in Focus: Stock Moves 11.7% Higher
by Zacks Equity Research
Valeant Pharmaceuticals International (VRX) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
Top Ranked Momentum Stocks to Buy for November 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 27th:
Top Ranked Momentum Stocks to Buy for November 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 22nd:
Collegium (COLL) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Collegium Pharmaceutical (COLL) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.
Top Ranked Momentum Stocks to Buy for November 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 16th:
Top Ranked Momentum Stocks to Buy for November 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 14th:
Collegium Pharmaceutical (COLL) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Collegium Pharmaceutical (COLL) shares rose 6% in the last trading session, amid huge volumes.
BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End
by Zacks Equity Research
BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.
BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls
by Zacks Equity Research
BioDelivery Sciences International (BDSI) reported wider-than-expected Q2 loss. However, Belbuca registered record sales for the second consecutive quarter.
Nektar's NKTR-181 Positive in Human Abuse Potential Study
by Zacks Equity Research
Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.
Nektar's Pain Drug Positive in Phase III Study; Shares Gain
by Zacks Equity Research
Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chronic low back pain.